Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1362 participants.
Also called NCT05249920
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,362 participants
- Sponsor
- Registry
-
NCT05249920
-
- Other papers using this trial's data
- Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05249920. Randomized; quadruple masking; primary purpose treatment. Start 2022-03-18 (actual); primary completion 2023-02-17 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)
- Condition
- Acute Ischemic Stroke
- Condition
- Mechanical Thrombectomy
- Condition
- Edaravone Dexborneol
- Condition
- Phase III
- Intervention (Drug)
- Edaravone Dexborneol Concentrated Solution for injection
- Intervention (Drug)
- Edaravone Dexborneol placebo
- Lead sponsor
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct05249920- Content hash
9dd11e177256202a7a47b0e47ac0f23f05d861926dcf96c3f0ddf9a7b254fbb5